Multi-institutional phase II study of docetaxel (D) and gemcitabine (G) as front-line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Amenedo, M
Mel, JR
Casal, J
Rodriguez, MR
Aparicio, LA
Constenla, M
Lopez, R
Almanza, C
Huarte, L
机构：
[1] Ctr Oncol Galicia, La Coruna, Spain
[2] Hosp Xeral Calde, Lugo, Spain
[3] Hosp Meixoeiro, Vigo, Spain
[4] Hosp Santa Maria Madre, Orense, Spain
[5] Hosp Juan Canalejo, La Coruna, Spain
[6] Complejo Hosp Pontevedra, Pontevedra, Spain
[7] CHUS, Santiago De Compostela, Spain
[8] POVISA, Vigo, Spain
[9] Aventis Pharma, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
511P
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [41] A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study
    Tabata, Masahiro
    Kozuki, Toshiyuki
    Ueoka, Hiroshi
    Kiura, Katsuyuki
    Harita, Shingo
    Tada, Atsuhiko
    Shibayama, Takuo
    Takigawa, Nagio
    Yonei, Toshiro
    Gemba, Kenichi
    Segawa, Yoshihiko
    Kishino, Daizo
    Tada, Shinya
    Hiraki, Shunkichi
    Tanimoto, Mitsune
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 53 - 59
  • [42] Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC)
    Ferrigno, D
    Buccheri, G
    LUNG CANCER, 2004, 45 (03) : 373 - 380
  • [43] Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    Stathopoulos, G. P.
    Katis, C.
    Tsavdaridis, D.
    Dimitroulis, J.
    Karaindros, D.
    Stathopoulos, J.
    Dimou, E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 555 - 560
  • [44] Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    G. P. Stathopoulos
    C. Katis
    D. Tsavdaridis
    J. Dimitroulis
    D. Karaindros
    J. Stathopoulos
    E. Dimou
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 555 - 560
  • [45] Phase II clinical trial on docetaxel in the treatment of non-small-cell lung cancer (NSCLC).
    Chen, Y
    Zhao, Y
    Chen, Z
    Liao, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 708S - 708S
  • [46] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    McCleod, M
    Treat, J
    Christiansen, NP
    Mintzer, DM
    Bonomi, P
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 650S - 650S
  • [47] PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CISPLATIN AND VINORELBINE AS FIRST LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED OR METASTATIC, NON SQUAMOUS, NON-SMALL-CELL LUNG CANCER (NSCLC)
    Leon, L.
    Gracia, J. M.
    Vazquez, S.
    Firvida, J. L.
    Amenedo, M.
    Casal, J.
    Gallego, R.
    Lazaro, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 121 - 121
  • [48] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    Fukuoka, M
    Yano, S
    Giaccone, G
    Tamura, T
    Nakagawa, K
    Douillard, JY
    Nishiwaki, Y
    Vansteenkiste, J
    Kudoh, S
    Rischin, D
    Eek, R
    Horai, T
    Noda, K
    Takata, I
    Smit, E
    Averbuch, S
    Macleod, A
    Feyereislova, A
    Dong, RP
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
  • [49] FIRST TREATMENT CHOICE FOR PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PRESENTING WITH BRAIN METASTASIS (BM): A PRELIMINARY REPORT ON A MULTI-INSTITUTIONAL SURVEY
    Pollera, C. F.
    Moscetti, L.
    Nelli, F.
    Cortesi, E.
    D'Auria, G.
    Ceratti, A. De Pasquale
    Gamucci, T.
    Mansueto, G.
    Ceribelli, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 28 - 28
  • [50] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Valerie Israel
    Scott T. Tagawa
    Terry Snyder
    Susan Jeffers
    Derek Raghavan
    Investigational New Drugs, 2004, 22 : 291 - 297
12345